Clovis Oncology, Inc.
https://clovisoncology.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Clovis Oncology, Inc.
ARCH Cites Stability Of Long-Term Investors In Raising $3bn Fund
ARCH Venture Partners brought in $2.975bn for its latest fund to give additional long-term investors a place at the table as the VC firm creates, builds and supports new early-stage biotechnology start-ups.
AstraZeneca/Merck Reinforce Lynparza’s Prostate Cancer Position With First-Line Data
The companies published data showing the drug was effective in patients with both homologous recombinant repair mutated and non-mutated disease.
Clovis Withdraws Rubraca Ovarian Cancer Indication Due To Survival Imbalance
Third-line BRCA-mutated ovarian cancer indication is not a major loss for Rubraca, but Clovis also faces delay in filing to add first-line ovarian cancer therapy to product label.
Stock Watch: Rare Diseases Beget Rare Profitability
Do rare disease drugs with tiny patient populations lie outside the profitability continuum that runs from small-molecule primary care products to specialist biologics?
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
- Other Names / Subsidiaries
-
- Ethical Oncology Science S.p.A. (EOS S.p.A.)